Multi-stakeholder sessions on major innovation topics in rare disease clinical trials
2024

Innovations in Rare Disease Clinical Trials

Sample size: 30 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bodden Daniel, Schoenen Stefanie, Wied Stephanie, Verbeeck Johan, Dirani Maya, Abou Daya Hiba, Heussen Nicole, Molenberghs Geert, Hilgers Ralf-Dieter, Nabbout Rima

Primary Institution: RWTH Aachen University

Hypothesis

How can innovative methodologies improve rare disease clinical trials?

Conclusion

A comprehensive educational program is essential for advancing methodologies in rare disease clinical trials.

Supporting Evidence

  • Training is needed for diverse stakeholders in rare disease clinical trials.
  • Challenges include a lack of standardized terminology for multiple endpoints.
  • Integrating innovations into tailored training programs is crucial for advancing the field.

Takeaway

This study talks about how to make clinical trials for rare diseases better by teaching people involved about new methods and ideas.

Methodology

Multi-stakeholder sessions with expert presentations and guided discussions.

Potential Biases

Misconceptions about randomization and allocation bias were identified.

Limitations

The study could not cover all aspects of innovation in rare disease clinical trials.

Participant Demographics

Participants included representatives from ERNs, patient organizations, the pharmaceutical industry, and academic institutions from various European countries.

Digital Object Identifier (DOI)

10.1186/s13023-024-03482-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication